Drugs / Savolitinib
Trials 48 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 117 trials | ||||||
| Phase 1 | NCT06348355 | Apr → Jun 2024 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05888207 | Jun → Aug 2023 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05768360 | Apr → Jun 2023 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04675021 | Nov 2020 → Jan 2021 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04187456 | Dec 2019 → Mar 2020 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04179071 | Dec 2019 → Mar 2020 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04121910 | Nov 2019 → Jan 2020 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04118842 | Oct 2019 → Feb 2020 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03598244 | Nov 2018 → Apr 2025 overdue | diffuse intrinsic pontine glioma, medulloblastoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03258515 | Sep 2017 → Mar 2018 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02630420 | Jan 2017 → Jan 2018 | colorectal cancer | Yale University | Withdrawn | No outcome recorded |
| Phase 1 | NCT02374645 | Apr 2015 → Feb 2018 | non-small cell lung carcinoma | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 1 | NCT02252913 | Sep 2014 → Dec 2015 | gastric cancer | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 1 | NCT02143466 | Aug 2014 → Mar 2020 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02017236 | Nov 2013 → Mar 2014 | — | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 1 | NCT01985555 | May 2013 → Apr 2019 | neoplasm | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 1 | NCT01773018 | Feb 2012 → Dec 2015 | neoplasm | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07683403 | Jun 2026 → Jun 2028 expected | colorectal cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05777278 | Jul 2023 → Aug 2027 expected | non-small cell lung carcinoma | The First Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02447406 | Apr 2015 → Jun 2020 | gastric adenocarcinoma | Samsung Medical Center | Completed | No outcome recorded |
| Phase 222 trials | ||||||
| Phase 2 | NCT07322783 | Jan 2025 → Dec 2026 expected | non-small cell lung carcinoma | Qingdao Central Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06692491 | Jan 2025 → Dec 2027 expected | — | Peking University Shenzhen Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06563999 | Nov 2024 → Nov 2027 expected | lung carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT05620628 | Jan 2023 → Dec 2026 expected | gastric adenocarcinoma | Jeeyun Lee | Recruiting | No outcome recorded |
| Phase 2 | NCT05374603 | Nov 2022 → Jan 2027 expected | lung cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05163249 | May 2022 → Apr 2024 overdue | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04923932 | Jul 2021 → Apr 2026 | gastric cancer, gastroesophageal junction adenocarcinoma | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 2 | NCT04606771 | Sep 2020 → Dec 2022 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04322890 | Apr 2020 → Dec 2026 expected | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04322578 | Mar 2020 → Mar 2025 | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03833440 | Oct 2019 → Oct 2024 | non-small cell lung carcinoma | Assistance Publique Hopitaux De Marseille | Unknown | No outcome recorded |
| Phase 2 | NCT03592641 | Jul 2019 → Jul 2021 | colon adenocarcinoma, rectum adenocarcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT03944772 | Jun 2019 → May 2025 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03778229 | Jan 2019 → Aug 2024 overdue | carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03385655 | Aug 2018 → Oct 2024 overdue | prostate cancer | Canadian Cancer Trials Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02447380 | Jul 2017 → Feb 2019 | gastric adenocarcinoma | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02897479 | Dec 2016 → Dec 2021 | lung sarcomatoid carcinoma | Hutchison Medipharma Limited | Unknown | No outcome recorded |
| Phase 2 | NCT02761057 | Jul 2016 → Oct 2023 | papillary renal cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02819596 | May 2016 → Jul 2024 | clear cell renal carcinoma, papillary renal cell carcinoma | Queen Mary University of London | Completed | No outcome recorded |
| Phase 2 | NCT02449551 | Feb 2016 → Dec 2020 | gastric adenocarcinoma | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02127710 | Apr 2014 → Apr 2016 | papillary renal cell carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT02117167 | Apr 2014 → Dec 2018 | non-small cell lung carcinoma | UNICANCER | Completed | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT05261399 | Aug 2022 → Jun 2026 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05015608 | Nov 2021 → Aug 2025 | non-small cell lung carcinoma | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 3 | NCT05043090 | Oct 2021 → Dec 2025 overdue | papillary renal cell carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05009836 | Sep 2021 → May 2028 expected | non-small cell lung carcinoma | Hutchison Medipharma Limited | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04923945 | Aug 2021 → Nov 2024 | non-small cell lung carcinoma | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 3 | NCT03091192 | Jul 2017 → Aug 2019 overdue | renal cell carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 51 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Savolitinib | “Phase 1 safety data of savolitinib (also known as AZD6094, HMPL-504, volitinib), a potent, selective MET TKI, plus osimertinib, a third-generation EGFR TKI, have provided...” PMID 32027846 ↗ Feb 202039“Savolitinib (AZD6094, HMPL-504, volitinib) is an oral, bioavailable, selective MET-tyrosine kinase inhibitor.” PMID 33400845 ↗ Jan 2021 “Savolitinib (volitinib, HMPL-504, AZD6094) is an oral, potent, and highly selective MET-TKI.” PMID 33052556 ↗ Oct 2020 “Savolitinib 300mg po, qd.” NCT04322578 ↗ “Drug: Savolitinib” NCT03091192 ↗ |
| Known as | AZD6094 | “Phase 1 safety data of savolitinib (also known as AZD6094, HMPL-504, volitinib), a potent, selective MET TKI, plus osimertinib, a third-generation EGFR TKI, have provided...” PMID 32027846 ↗ Feb 20206“Savolitinib (AZD6094, HMPL-504) is a highly selective MET-TKI which has demonstrated anti-tumor activity in various cancers with MET alterations.” PMID 36333268 ↗ Sep 2022 “The Sponsor is developing the test medicine, AZD6094 (Savolitinib) for the potential treatment of cancer.” NCT04675021 ↗ |
| Known as | HMPL-504 | “Phase 1 safety data of savolitinib (also known as AZD6094, HMPL-504, volitinib), a potent, selective MET TKI, plus osimertinib, a third-generation EGFR TKI, have provided...” PMID 32027846 ↗ Feb 20202“Savolitinib (AZD6094, HMPL-504, volitinib) is an oral, bioavailable, selective MET-tyrosine kinase inhibitor.” PMID 33400845 ↗ Jan 2021 “Volitinib(HMPL-504)” NCT01985555 ↗ |
| Known as | volitinib | “Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in...” NCT02447406 ↗8“Phase 1 safety data of savolitinib (also known as AZD6094, HMPL-504, volitinib), a potent, selective MET TKI, plus osimertinib, a third-generation EGFR TKI, have provided...” PMID 32027846 ↗ Feb 2020 “Savolitinib (AZD6094, HMPL-504, volitinib) is an oral, bioavailable, selective MET-tyrosine kinase inhibitor.” PMID 33400845 ↗ Jan 2021 |
| Action | Inhibit | “inhibitor of c-Met kinase” NCT01773018 ↗ |
| Modality | Small molecule | “small molecule inhibitor of c-Met kinase” NCT01773018 ↗ |
| Route | Oral | “administered orally” NCT01773018 ↗ |
| Target | MET | “small molecule inhibitor of c-Met kinase” NCT01773018 ↗ |